Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
Dr. Dere brings to Seres more than two decades of scientific, clinical,
and strategic biopharmaceutical experience. He is currently Professor of
Internal Medicine, Executive Director of
“Willard Dere is a highly distinguished industry leader with deep
clinical development and strategic industry expertise,” said Roger J.
Pomerantz, M.D., President, CEO and Chairman of Seres. “I am extremely
pleased to welcome Willard to the Seres Board during this important
period, where Seres is developing SER-109 as the first Phase 3 stage
microbiome therapeutic candidate and which may be the first ever
Dr. Dere commented: “Seres is advancing a promising pipeline of
microbiome product candidates using a highly differentiated scientific
approach. I am eager to contribute to the company’s objective of
bringing the first
Biographical Background
Dr. Dere serves as the Professor of Internal Medicine; B. Lue and Hope
S. Bettilyon Presidential Endowed Chair in Internal Medicine for
Diabetes Research, Executive Director of
About Seres Therapeutics
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Seres’ goals and objectives, the potential impact of Seres’ microbiome therapeutics platform, expectations regarding Seres’ pipeline, and Dr. Dere’s potential contribution to Seres.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding, which may not be available;
our limited operating history; the unpredictable nature of our early
stage development efforts for marketable drugs; the unproven approach to
therapeutic intervention of our microbiome therapeutics; the lengthy and
expensive process of clinical drug development, which has an uncertain
outcome; potential delays in enrollment of patients which could affect
the receipt of necessary regulatory approvals; potential delays in
regulatory approval, which would impact the ability to commercialize our
product candidates and affect our ability to generate revenue; any fast
track or Breakthrough Therapy designation may not lead to faster
development, regulatory approval or marketing approval; our possible
inability to receive orphan drug designation should we choose to seek
it; our reliance on third parties to conduct our clinical trials and the
potential for those third parties to not perform satisfactorily; our
reliance on third parties to manufacture our product candidates, which
may delay, prevent or impair our development and commercialization
efforts; our lack of experience in manufacturing our product candidates;
the potential failure of our product candidates to be accepted on the
market by the medical community; our lack of experience selling,
marketing and distributing products and our lack of internal capability
to do so; failure to compete successfully against other drug companies;
potential competition from biosimilars; failure to obtain marketing
approval internationally; post-marketing restrictions or withdrawal from
the market; anti-kickback, fraud, abuse, and other healthcare laws and
regulations exposing us to potential criminal sanctions; recently
enacted or future legislation; compliance with environmental, health,
and safety laws and regulations; protection of our proprietary
technology; protection of the confidentiality of our trade secrets;
changes in
View source version on businesswire.com: http://www.businesswire.com/news/home/20170710005426/en/
Source:
IR and PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com